Recombinant Yeast Heparosan Production via Enzyme Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing heparin and heparan sulfates rely on animal tissues, leading to contamination and supply issues, and existing microbial production faces challenges in cost-efficiency, high product titers, and precise sulfation pattern control.
Innovation Solution
Engineering recombinant yeast strains, specifically Saccharomyces cerevisiae, to efficiently produce UDP-D-glucuronic acid, UDP-N-acetyl-D-glucosamine, and 3'-phospho-adenylylsulfate, and expressing bacterial heparosan synthases with nuclear export sequences to achieve high titers of heparosan and heparan sulfates with defined sulfation patterns.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If animal tissues are used as the source of heparin, then the production meets current demand, but contamination and supply shortages occur during animal disease outbreaks
Solution Approach 1:
The patent creates a recombinant yeast cell system that copies and reproduces the biosynthetic pathways for heparin and heparan sulfate production. By integrating bacterial heparosan synthase genes and vertebrate sulfotransferase genes into yeast, the system replicates the complex biosynthesis process in a controlled microbial environment, eliminating dependence on animal tissues while maintaining product quality and supply reliability
Solution Approach 2:
The patent uses recombinant yeast cells as an intermediary organism to produce heparin and heparan sulfates. The yeast serves as a bridge between microbial biosynthesis capabilities and vertebrate glycosaminoglycan production requirements, expressing both bacterial and vertebrate enzymes in a single eukaryotic system to achieve reliable, contamination-free production
2Productivity
If conventional animal tissue sources are used, then heparin production is established, but cost efficiency and high product titers are not achieved
Solution Approach 1:
The recombinant yeast cell system is engineered to self-produce all necessary enzymes and precursors for heparin and heparan sulfate synthesis. The yeast endogenously produces UDP-glucuronic acid and UDP-N-acetyl-glucosamine precursors, while simultaneously expressing bacterial heparosan synthase and vertebrate sulfotransferase enzymes, creating a self-sufficient biosynthetic platform that eliminates complex multi-step manufacturing processes and reduces production costs
Solution Approach 2:
The yeast cell system performs multiple functions simultaneously: it produces precursor sugars, synthesizes heparosan backbone, and carries out sequential sulfation reactions to generate both heparin and heparan sulfates. This multi-functional platform increases productivity by consolidating multiple biosynthetic steps into a single organism, thereby reducing manufacturing complexity and cost
3Manufacturing precision
If bacterial enzymes are used for heparosan synthesis, then production is simplified, but precise sulfation pattern control is lost
Solution Approach 1:
The patent expresses multiple specialized sulfotransferase enzymes (NDST1, C5-epimerase, HS2ST1, HS3ST1, HS6ST1) that each catalyze specific sulfation reactions at particular positions on the heparosan backbone. This localized enzymatic action enables precise control over sulfation patterns, creating distinct heparin and heparan sulfate structures with defined biological activities while managing enzyme system complexity through modular gene expression
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach creates a cost-effective, high-yield production platform for heparan sulfates with controlled sulfation patterns, overcoming the limitations of animal-derived sources and enabling industrial-scale production for diverse medical applications.
Implementation Method 1
recombinant yeast cells that produce an increased amount of UDP-D-glucuronic acid and/or UDP-N-acetyl-D-glucosamine
Implementation Method 2
expressing bacterial heparosan synthases with nuclear export sequences to achieve high titers of heparosan
Implementation Method 3
all enzymes required for heparosan modification, i.e. for heparan sulfate and heparin biosynthesis
Data Source
Figure 1a
Figure 1b
Figure 2a
AI summary
The present invention refers to recombinant yeast cells that produce an increased amount of UDP-D-glucuronic acid and/or UDP-N-acetyl-D-glucosamine; and optionally 3'-phospho-adenylylsulfate, when compared to its wildtype cells. The present invention further refers to a method of producing heparan sulfate, comprising a step of cultivating the recombinant yeast cell of the present invention, to the use of said invneitve recombinant yeast cell for producing heparan sulfate, and finally to heparan sulfates obtained when applying the method of the present invention.